In June 2020, BSV formed a strategic alliance with LaVoieHealthScience in order to enhance BSV's capabilities to communicate value. <read more here>                     In May 2020, BSV entered into a strategic alliance with FCF Fox Corporate Finance to support funding activities. <read more here>                    
 
                           COVID-19 Portal               Home      About      Team      Clients      Publications      Downloads      News      Career      Contact

Testimonials
  Bioscience Valuation's comprehensive assessments of in-licensing candidates provide us with a thorough understanding of the opportunity, both from a scientific and business perspective.

Dr. Philipp R. Hoffmann, Senior Director Business Development & Licensing Europe, Daiichi Sankyo

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Core Services - Partnering / Licensing

Bioscience Valuation supports senior management in Partnering (e.g., in- and outlicensing) efforts:
  • full evaluation of the asset, including all commercial, R&D and financial attributes,
  • creation of long and short lists of potential partners,
  • initiating contact and communication between client and target company,
  • drafting term sheets,
  • supporting the negotiations until an agreement has been signed,
  • monitoring partnership progress and ensuring satisfaction of all parties after the deal.


Case:
A leading Southern-European company was searching for in-licensing opportunities. Bioscience Valuation (BSV) screened the worldwide pharmaceutical markets in a comprehensive and systematic way.

Bioscience Valuation identified promising drugs that were EMA-approved and ready to get marketed; BSV drafted the term sheet and supported the negotiations. Bioscience Valuation's client licensed the drug that is now distributed in the local market.




This website uses cookies to ensure you get the best experience on our website.
Privacy Policy